---
document_datetime: 2025-01-24 16:13:49
document_pages: 30
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/imvanex-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: imvanex-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 16.8062875
conversion_datetime: 2025-12-20 10:24:26.149635
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## IMVANEX

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                 |
|----------------------|---------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0107               | 11th annual re-assessment | 14/11/2024                          | 13/01/2025                                  | Annex II                         | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of IMVANEX should be maintained. Annex II of the PI is ammended to remove the following |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                     |            |     | SOB, since the final study report has been submitted To ensure adequate monitoring of safety and effectiveness, the MAH shall perform the following study to collect data where IMVANEX is used as a prophylactic vaccine and/or use in case of (re) emergence of circulating monkeypox. Non-interventional post-authorisation efficacy study (PAES): An observational, non-interventional post- authorisation safety and efficacy study for the prophylactic vaccination with IMVANEX following (re)-emergence of circulating monkeypox infections. The study should start as soon as possible after the start of the outbreak The following obligation is added to the Annex II in alignment with other products authorised via exceptional circumstances. In order to ensure adequate monitoring of safety and efficacy of IMVANEX in the active immunisation against smallpox and disease caused by vaccinia virus, the MAH shall provide yearly updates on any new information concerning the safety and efficacy of IMVANEX.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0106   | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range | 14/11/2024 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IB/0109/G | This was an application for a group of variations.                                                                                                  | 01/10/2024 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|                     | A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                        |                                                                        |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------|
| II/0108             | Extension of indication to include active immunisation of adolescents from 12 to 17 years of age for IMVANEX based on interim results from study DMID 22-0020. This is a Phase 2 randomised open label multicentre trial to inform Public Health strategies involving the use of MVA-BN vaccine for mpox. As a consequence, sections 4.1, 4.2, 4.8, and 5.1 of the SmPC and Annex II.E are updated. The Package Leaflet is updated in accordance. Furthermore, the PI is brought in line with the latest QRD template version 10.4. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or | 19/09/2024 | 19/09/2024 | SmPC, Annex II and PL  | Please refer to Scientific Discussion Imvanex- EMEA/H/C/002596/II/0108 |
| PSUSA/10119 /202401 | Periodic Safety Update EU Single assessment - Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 05/09/2024 | n/a        |                        | PRAC Recommendation - maintenance                                      |
| II/0104/G           | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for                                                                                                                                                                                                                                                                                                                                                                                      | 25/07/2024 | 19/09/2024 | SmPC, Labelling and PL |                                                                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.b.z - Change in manufacture of the Finished Product - Other variation B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within   |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0100 | Update of section 5.1 of the SmPC in order to add vaccine effectiveness data based on the IMVANEX vaccine effectiveness data in real-world use during the 2022 mpox outbreak. The RMP version 10.2 has also been submitted. Furthermore, the PI is brought in line with the latest QRD template version 10.4. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                   | 25/07/2024 | 19/09/2024 | SmPC, Annex II and PL | SmPC section 5.1 Vaccine effectiveness In real-world observational studies conducted in vaccine- eligible individuals (according to local recommendations), vaccine effectiveness against mpox disease was demonstrated at least 14 days after vaccination, with adjusted vaccine effectiveness estimates ranging from 35% (95% CI, -2-59) to 89% (95% CI, 76-95) after one IMVANEX dose and from 66% (95% CI, 47-78) to 90% (95% CI, 86-92) after two IMVANEX doses. Impact on hospitalisation In a surveillance study conducted from May 2022 to May |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                            |            |            |             | 2023 in the US, IMVANEX was shown to reduce the risks of mpox-related hospitalisation. Compared with unvaccinated mpox patients, the odds of hospitalisation were 0.27 (95% CI, 0.08-0.65) after one IMVANEX dose, and 0.20 (95% CI, 0.01 0.90) after two IMVANEX doses. The estimated relative risk reduction was 73% after one IMVANEX dose and 80% after two IMVANEX doses. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0105/G           | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 09/07/2024 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| PSUSA/10119 /202307 | Periodic Safety Update EU Single assessment - Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)                                                                                                                                                                                                         | 21/03/2024 | 16/05/2024 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10119/202307.                                                                                                                                                                                                                                                                                                                     |
| IB/0102/G           | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.4.c - Change to in-process tests or limits           | 29/04/2024 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|           | applied during the manufacture of the AS - Deletion of a non-significant in-process test                                                                                                                                                                                                                                                                                                                                                                                            |            |     |                                                                                                                                                                                                                                                                  |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0101/G | This was an application for a group of variations. B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or | 26/02/2024 | n/a |                                                                                                                                                                                                                                                                  |
| S/0095    | 10th annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 22/02/2024 | n/a | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of IMVANEX should be maintained. |
| IB/0099   | B.I.b.z - Change in control of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                             | 26/01/2024 | n/a |                                                                                                                                                                                                                                                                  |
| IB/0097   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                          | 09/11/2023 | n/a |                                                                                                                                                                                                                                                                  |
| IA/0098   | B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits                                                                                                                                                                                                                                                                                                                                     | 30/10/2023 | n/a |                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| IB/0094             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                             | 21/09/2023   | n/a   |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| IB/0093/G           | This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation | 05/09/2023   | n/a   |                                   |
| PSUSA/10119 /202301 | Periodic Safety Update EU Single assessment - Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)                                                                                                                                                       | 31/08/2023   | n/a   | PRAC Recommendation - maintenance |
| IB/0092/G           | This was an application for a group of variations. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                              | 01/08/2023   | n/a   |                                   |
| IA/0090             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                            | 19/04/2023   | n/a   |                                   |
| II/0084/G           | This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial                                                                                                                   | 16/03/2023   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

|                     | change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |     |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| II/0081             | Submission of an updated RMP version 9.3 in order to update the safety specifications in line with extension of the indication to 'active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults', update the missing information from the list of safety concerns, differentiate routine pharmacovigilance activities and additional pharmacovigilance activities, addition of non-BN sponsored clinical study SEMVAc to additional pharmacovigilance activities and deletion of paediatric study POX-MVA-035 upon request by PRAC following the assessment of procedure II/76. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 16/03/2023 | n/a |                                   |
| PSUSA/10119 /202207 | Periodic Safety Update EU Single assessment - Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 16/03/2023 | n/a | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IAIN/0089/G   | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within                                                                                                       | 15/03/2023   | 22/09/2023   | SmPC, Labelling and PL   |                     |
|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|---------------------|
| IB/0088/G     | This was an application for a group of variations. B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation A.7 - Administrative change - Deletion of | 20/02/2023   | n/a          |                          | manufacturing sites |
| IB/0087       | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                          | 14/02/2023   | n/a          |                          |                     |
| IB/0083       | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                 | 03/02/2023   | n/a          |                          |                     |
| II/0079       | B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS                                                                                                                       | 26/01/2023   | n/a          |                          |                     |

<div style=\"page-break-after: always\"></div>

| N/0086              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                        | 22/12/2022   | 22/09/2023   | Labelling   |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|-----------------------------------|
| IB/0085             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                            | 21/12/2022   | n/a          |             |                                   |
| IB/0082             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                  | 29/11/2022   | n/a          |             |                                   |
| S/0077              | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                   | 10/11/2022   | n/a          |             |                                   |
| IB/0078/G           | This was an application for a group of variations. B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved | 21/10/2022   | 22/09/2023   | SmPC and PL | Shelf-life update                 |
| PSUSA/10119 /202201 | Periodic Safety Update EU Single assessment - Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)                                                                                                                                                                                                                                                                                      | 01/09/2022   | n/a          |             | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| II/0076   | - Change(s) to therapeutic indication(s) - of a new therapeutic indication or of an approved one                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 21/07/2022   | 22/07/2022   | SmPC, Labelling and PL   | C.I.6.a Addition modification   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|---------------------------------|
| II/0075/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.e.1.z - Change in immediate packaging of the finished product - Other variation B.II.c.z - Change in control of excipients in the Finished Product - Other variation B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging | 21/07/2022   | n/a          |                          | site                            |
| IB/0073/G | This was an application for a group of variations. B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 13/04/2022   | n/a          |                          |                                 |

<div style=\"page-break-after: always\"></div>

|                     | storage site of MCB and/or WCB                                                                                                                                                                                                             |            |            |          |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------------------------------|
| PSUSA/10119 /202107 | Periodic Safety Update EU Single assessment - Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)                                                                                                                         | 10/03/2022 | n/a        |          | PRAC Recommendation - maintenance |
| IB/0072             | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                        | 22/12/2021 | n/a        |          |                                   |
| S/0069              | Annual re-assessment.                                                                                                                                                                                                                      | 11/11/2021 | n/a        |          |                                   |
| IAIN/0070           | C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority | 01/10/2021 | 22/07/2022 | Annex II |                                   |
| PSUSA/10119 /202101 | Periodic Safety Update EU Single assessment - Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)                                                                                                                         | 02/09/2021 | n/a        |          | PRAC Recommendation - maintenance |
| IB/0067             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                     | 26/08/2021 | n/a        |          |                                   |
| IB/0068             | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                        | 25/08/2021 | n/a        |          |                                   |

<div style=\"page-break-after: always\"></div>

| II/0064             | B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product                                 | 01/07/2021   | n/a   |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| IB/0063             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                    | 10/05/2021   | n/a   |                                   |
| IB/0065             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                    | 04/05/2021   | n/a   |                                   |
| PSUSA/10119 /202007 | Periodic Safety Update EU Single assessment - Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)                                                                                                                                     | 11/03/2021   | n/a   | PRAC Recommendation - maintenance |
| IB/0061             | B.II.f.z - Stability of FP - Other variation                                                                                                                                                                                                           | 18/12/2020   | n/a   |                                   |
| IA/0062             | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                    | 17/12/2020   | n/a   |                                   |
| IA/0060/G           | This was an application for a group of variations. B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting material/reagent/intermediate, if an alternative test | 11/12/2020   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

| procedure is already B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.c - Change in and/or limits of an AS, material/intermediate/reagent specification parameter corresponding test method B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.b - Change in   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of   |            |     |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0058/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor                                                                                                                                                                                                                                                                                                                                                                                                                                        | 09/12/2020 | n/a |

<div style=\"page-break-after: always\"></div>

|             | changes to an approved test procedure                                                                                                                                                                                                                                                                                                 |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0055     | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product                                                                                                   | 26/11/2020 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0050     | B.I.a.1.d - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New manufacturer of material for which an assessment is required of viral safety and/or TSE risk                                                                                                                                 | 19/11/2020 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IAIN/0059/G | This was an application for a group of variations. B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.1.b - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits for medicinal products subject to OCABR | 18/11/2020 | 16/04/2021 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| S/0054      | Annual re-assessment.                                                                                                                                                                                                                                                                                                                 | 12/11/2020 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0049     | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol                                                                            | 01/10/2020 | 16/04/2021 | SmPC and PL | As a result of this variation, sections 2 and 4.3 of the SmPC are being updated to reflect the newly added trace residue of ciprofloxacin. In addition, the list of residues traces in the SmPC section 2 has been updated with the following compounds chicken protein, benzonase, and gentamicin, which were already mentioned in section 4.3. The company takes the opportunity to correct section 2 to align the contents with section 4.3. The Package Leaflet (PL) is |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                               |            |     | updated accordingly in section 2 and 6. In addition, update of section 4.4, including the traceability statement, and Annex II according to the current QRD template together with the inclusion of the statement for sodium as an excipient, according to the excipient guideline, were implemented.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0052   | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                    | 17/09/2020 | n/a |                                                                                                                                                                                                                                                                                                         |
| IB/0051   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                  | 14/09/2020 | n/a |                                                                                                                                                                                                                                                                                                         |
| IB/0056/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 03/09/2020 | n/a |                                                                                                                                                                                                                                                                                                         |
| II/0047/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS -                                                                                                                                                                       | 03/09/2020 | n/a |                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|                     | the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place   |            |            |             |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| PSUSA/10119 /202001 | Periodic Safety Update EU Single assessment - Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)                                                                                                                                                                                                                                                                                                                                                                                 | 03/09/2020 | n/a        |             | PRAC Recommendation - maintenance |
| IB/0053/G           | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.d.1.b.3 - Stability of AS - Change in the storage conditions - Change in storage conditions of the AS                                                                                                                                                                | 01/09/2020 | n/a        |             |                                   |
| IB/0048             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                  | 08/06/2020 | 16/04/2021 | SmPC and PL |                                   |
| IB/0043             | B.I.c.1.a - Change in immediate packaging of the AS - Qualitative and/or quantitative composition                                                                                                                                                                                                                                                                                                                                                                                                  | 23/04/2020 | n/a        |             |                                   |

<div style=\"page-break-after: always\"></div>

| IAIN/0046   | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 10/04/2020   | 16/04/2021   | SmPC, Labelling and PL   |             |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-------------|
| IAIN/0044/G | This was an application for a group of variations. B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR B.I.b.1.a - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits for medicinal products subject to OCABR B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of parameter) | 10/04/2020   | n/a          |                          | an obsolete |

<div style=\"page-break-after: always\"></div>

|                     | changes to an approved test procedure                                                                              |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------|--------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10119 /201907 | Periodic Safety Update EU Single assessment - Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara) | 13/02/2020 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| S/0041              | 6th annual re-assessment                                                                                           | 14/11/2019 | n/a        |             | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of IMVANEX should be maintained.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| PSUSA/10119 /201901 | Periodic Safety Update EU Single assessment - Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara) | 05/09/2019 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0036             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data  | 11/04/2019 | 09/03/2020 | SmPC and PL | Imvanex was compared to ACAM2000 (a 'second generation' live attenuated smallpox vaccine produced in cell culture and licenced in the United States of America) in a randomized, open-label non-inferiority clinical trial in healthy adults (US military personnel) aged 18 to 42 years and who were nave to smallpox vaccine (Study POX-MVA- 006). A total of 433 subjects were randomized in a 1 : 1 ratio to receive either two doses of Imvanex followed by a single dose of ACAM2000 at four weeks intervals or to receive a single dose of ACAM2000. ACAM2000 was administered via scarification. The first co-primary endpoint compared vaccinia-specific neutralizing antibody responses at the peak visits (Day 42 after first vaccination for Imvanex where the subjects received two doses according to the standard vaccination |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |             | schedule and Day 28 for ACAM2000). Imvanex induced a peak neutralizing antibody geometric mean titer (GMT) of 153.5 (n = 185; 95% CI 134.3, 175.6), which was non- inferior to the GMT of 79.3 (n = 186; 95% CI 67.1, 93.8) obtained after scarification with ACAM2000. The second co-primary endpoint evaluated if vaccination with Imvanex (n = 165) prior to administration of ACAM2000 results in an attenuation of the cutaneous reaction to ACAM2000 (n = 161) as measured by maximum lesion area in mm2. At day 13-15, the median maximum lesion area for subjects who were administered ACAM2000 was 75mm2 (95% CI 69.0, 85.0) and for those who received Imvanex it was 0.0 (95% CI 0.0, 2.0).   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0035 | Update of sections 4.4 and 4.8 of the SmPC in order to reflect the final results of study POX-MVA-037 (phase II, randomised, open-label, multicentre trial designed to evaluate the safety and immunogenicity of IMVANEX (MVA-BN smallpox vaccine) when increasing the dose or the number of injections compared with the standard 2-dose regimen in a population of adult, vaccinia naive, immunocompromised subjects with human immunodeficiency virus (HIV) infection), listed as a category 3 study in the RMP (described as post authorisation MEA 007); The RMP version 7.1 has also been submitted. Moreover, the PI is brought in line with the latest QRD template version 10. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 14/03/2019 | 09/03/2020 | SmPC and PL | Data have been generated in HIV infected individuals with CD4 counts 100 cells/l and 750 cells/l. Lower immune response data have been observed in HIV infected individuals compared to healthy individuals.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| IB/0039/G           | This was an application for a group of variations. B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol   | 13/03/2019   | 09/03/2020   | SmPC, Labelling and PL   |                                                                                                                                                                                                                                                                       |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10119 /201807 | Periodic Safety Update EU Single assessment - Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)                                                                                                                                                                                                                                   | 14/02/2019   | n/a          |                          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                     |
| S/0037              | 5th annual re-assessment                                                                                                                                                                                                                                                                                                                             | 15/11/2018   | n/a          |                          | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Imvanex should be maintained.      |
| PSUSA/10119 /201801 | Periodic Safety Update EU Single assessment - Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)                                                                                                                                                                                                                                   | 06/09/2018   | n/a          |                          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                     |
| R/0032              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                              | 22/02/2018   | 23/04/2018   |                          | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of IMVANEX in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| PSUSA/10119 /201707 | Periodic Safety Update EU Single assessment - Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)                                                                                                                                                                                                                                   | 08/02/2018   | n/a          |                          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| IB/0033             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                              | 30/01/2018   | 23/04/2018   | SmPC                   |                                                                                                                                                                                                                                                                 |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0029              | Annual re-assessment.                                                                                                                                                                                                                            | 09/11/2017   | n/a          |                        | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of IMVANEX should be maintained |
| IB/0030             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                    | 06/11/2017   | n/a          |                        |                                                                                                                                                                                                                                                                 |
| II/0027             | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS | 14/09/2017   | 15/11/2017   | SmPC, Labelling and PL | SmPC Section 2 and 4.8 has been updated as follows: One dose (0.5 ml) contains: Modified Vaccinia Ankara - Bavarian Nordic Live virus1 no less than 5 x 107 Inf.U * *infectious units                                                                           |
| PSUSA/10119 /201701 | Periodic Safety Update EU Single assessment - Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)                                                                                                                               | 01/09/2017   | n/a          |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                               |
| IB/0026             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                    | 11/04/2017   | 15/11/2017   | Annex II               |                                                                                                                                                                                                                                                                 |
| PSUSA/10119         | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                    | 09/02/2017   | n/a          |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| /201607             | Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)                                                                                                                                                                                                                                                                                                                                |            |            |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0022              | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                               | 10/11/2016 | 06/02/2017 | Annex II | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that Marketing Authorisation of IMVANEX should be maintained. The SOB1 in Annex II of the Product Information is deleted, as the MAH has provided adequate information to reassure that assays used to measure antibody titres over time are adequately validated. |
| IB/0025/G           | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 11/01/2017 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IB/0024             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                 | 23/11/2016 | 15/11/2017 | SmPC     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| PSUSA/10119 /201601 | Periodic Safety Update EU Single assessment - Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)                                                                                                                                                                                                                                                                                  | 02/09/2016 | n/a        |          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| II/0018             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 26/05/2016   | 12/08/2016   | SmPC and PL           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0020             | Update of sections 4.8 and 5.1 of the SmPC based on data from Study MVA-POX-013, a randomised, double-blind, placebo-controlled phase III trial to evaluate immunogenicity and safety of three consecutive production lots of Imvanex (MVA-BN) smallpox vaccine in healthy vaccinia-naive subjects. The Package Leaflet has been updated accordingly. The provision of the study report addresses the post- authorisation measure (PAM) ANX 003, which has been deleted accordingly in Annex II. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 21/04/2016   | 12/08/2016   | SmPC, Annex II and PL | In the clinical study MVA-POX-013, three consecutive production lots of IMVANEX (MVA-BN) are compared. The data suggest comparable performance between lots. The combined groups 1-3 included 2119 healthy subjects and the PRNT and ELISA seroconversion rates for the pooled vaccine lots were 99.8% (95% CI: 99.5; 99.9) and 99.7% (95% CI: 99.4; 99.9), respectively. Further, the MAH has submitted an analysis of the safety data from the 3,000 subjects who were exposed across the three vaccine lots which were tested. The rates of adverse events were generally consistent across the lots. No new safety concerns are raised based on the information provided. |
| PSUSA/10119 /201507 | Periodic Safety Update EU Single assessment - Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 11/02/2016   | n/a          |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| S/0017              | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 28/01/2016   | n/a          |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| PSUSA/10119 /201501 | Periodic Safety Update EU Single assessment - Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 10/09/2015   | n/a          |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IB/0016             | B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 03/08/2015   | 18/09/2015   | SmPC, Annex           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|           | diluted/reconstituted product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |     | II and PL   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| IB/0015   | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 22/06/2015 | n/a |             |
| II/0013/G | This was an application for a group of variations. Submission of non-clinical final study reports for studies BN-PRE-2013-12 (Study for effects on embryo-fetal development by subcutaneous route in rats), BN-PRE-11-021 (Determination of the optimal dose of monkeypox for the aerosol challenge model in cynomolgus macaques and evaluation of efficacy and immunogenicity of IMVAMUNE), BN-PRE-011- 022 (Correlation of neutralising antibody titers with survival of cynomolgus monkeys in the aerosol monkeypox virus challenge model), BN-PRE-11-020 (Non-inferiority of the immunogenicity of freeze- dried IMVAMUNE compared to liquid-frozen IMVAMUNE in a BALB/c mouse model), BN-PRE-11- 024 (Non-inferiority of efficacy and immunogenicity of freeze-dried IMVAMUNE compared to liquid-frozen IMVAMUNE in the mouse vaccinia challenge model), BN-PRE-11-027 (Non-inferiority of efficacy and immunogenicity of freeze-dried IMVAMUNE compared to liquid-frozen IMVAMUNE in a mouse ectromelia challenge model). C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission | 26/03/2015 | n/a |             |

<div style=\"page-break-after: always\"></div>

|                     | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   |            |            |                        |                                                                                                                                                                                                                                                    |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10119 /201407 | Periodic Safety Update EU Single assessment - Smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 12/02/2015 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                  |
| IB/0012             | B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 15/12/2014 | 18/09/2015 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                    |
| S/0010              | 1st Annual Re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 20/11/2014 | n/a        |                        | The CHMP, having reviewed the evidence on compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of Imvanex, concluded that Marketing Authorisation of Imvanex should be maintained. |
| II/0008/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 25/09/2014 | 18/09/2015 | SmPC, Labelling and    | to introduce an alternative storage temperature of the finished product at -80C. The shelf-life of the finished                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|           | to introduce an alternative storage temperature of the finished product at -80C. The shelf-life of the finished product stored at -80C is 5 years. B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol B.II.f.1.c - Stability of FP - Change in storage conditions for biological medicinal products, when the stability studies have not been performed in accordance with an approved stability protocol   |            |            | PL          | product stored at -80C is 5 years.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0009   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                     | 03/09/2014 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| PSUV/0007 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 26/06/2014 | 22/08/2014 | SmPC and PL | Please refer to IMVANEX PSUV-07 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                       |
| II/0004/G | This was an application for a group of variations. Update of Section 4.8 of the SmPC to reflect pooled safety data from completed clinical trials. The PL is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance                                                                                                                               | 26/06/2014 | 22/08/2014 | SmPC and PL | Based on the results of a completed Clinical Study POX MVA 030 and a pooling of ADRs from all Imvanex studies, the MAH proposed changes to the Product Information (PI). Information was updated to amend the number of studies making up the source of the pooled Safety information and the number of patients constituting the dataset in the SmPC. The frequency of a number of adverse events was re-assigned based on the new figures. 'Chest pain' was added to the list of Side Effects observed with Imvanex. |

<div style=\"page-break-after: always\"></div>

| IB/0006   | B.I.a.3.e - Change in batch size (including batch size ranges) of AS or intermediate - The scale for a biological/immunological AS is increased/decreased without process change (e.g. duplication of line)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 04/03/2014   | n/a   |                   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------|
| IB/0005/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other | 23/01/2014   | n/a   | changes to a test |

<div style=\"page-break-after: always\"></div>

|           | the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting   |            |     | or addition) for material/intermediate   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------|
| IB/0003   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                     | 20/12/2013 | n/a |                                          |
| IAIN/0002 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                  | 09/12/2013 | n/a |                                          |
| IAIN/0001 | C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV and/or QPPV contact details and/or back-up procedure                                                                                                                                                                                                                                                                                     | 06/09/2013 | n/a |                                          |